# Shenzhen TargetRx

Source: https://onco.cc/companies/shenzhen-targetrx/  
OnCo record `shenzhen-targetrx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shenzhen TargetRx is a China-based biotechnology company running 4 late-stage cancer trials of TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma and acute myeloid leukaemia.

## Summary

Shenzhen TargetRx, based in Shenzhen, China, is a biotechnology company. TargetRx develops next-generation targeted small-molecule anticancer drugs designed to overcome drug resistance, using an AI-assisted, structure-based molecular design platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma, acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes / neoplasms. The largest, NCT06082635 (TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)), plans to enrol 321 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Shenzhen TargetRx Co., Ltd.
- Tags: ctgov-sponsor
- HQ: Shenzhen
- Type: biotech
- Website: https://www.tjrbiosciences.com

## Sources

- Official website: https://www.tjrbiosciences.com
- ClinicalTrials.gov: trials led by Shenzhen TargetRx: https://clinicaltrials.gov/search?lead=Shenzhen%20TargetRx%20Co.%2C%20Ltd.

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [TGRX-326](https://onco.cc/drugs/tgrx-326/)
- trials: [TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05955391/), [TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-3/), [TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients](https://onco.cc/trials/nct06453902/), [TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies](https://onco.cc/trials/nct06206174/)

---
JSON: https://onco.cc/api/v1/entities/shenzhen-targetrx.json